Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
NCT02180061
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Pembrolizumab
Sponsor
Merck Sharp & Dohme LLC